List of Excipients in Branded Drug CLEOCIN T

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	CLEOCIN T	clindamycin phosphate	0009-3116	ISOPROPYL ALCOHOL
Pharmacia & Upjohn Company LLC	CLEOCIN T	clindamycin phosphate	0009-3116	PROPYLENE GLYCOL
Pharmacia & Upjohn Company LLC	CLEOCIN T	clindamycin phosphate	0009-3116	WATER

CLEOCIN T Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Cleocin T is a topical clindamycin phosphate product for acne vulgaris. Its commercial opportunity is primarily in differentiated generic formulations, combination products, and tolerability-focused delivery systems rather than in the legacy brand itself. The core formulation challenge is balancing antimicrobial performance, skin feel, preservative protection, chemical stability, and resistance-management requirements.

What is CLEOCIN T and how is it regulated?

CLEOCIN T contains clindamycin phosphate, a water-soluble prodrug of clindamycin. The topical product is labeled for the treatment of acne vulgaris and is available in multiple dosage forms, including solution, gel, lotion, and foam presentations in U.S. regulatory records and labeling archives.[1-3]

Attribute	CLEOCIN T
Active ingredient	Clindamycin phosphate
Strength	1%, equivalent to 10 mg/mL or 10 mg/g clindamycin
Therapeutic class	Topical lincosamide antibiotic
Primary indication	Acne vulgaris
FDA pathway	New Drug Application and abbreviated new drug application pathways
Reference product sponsor history	The Upjohn/Pfizer organization and successor entities
Main dosage forms	Solution, gel, lotion, foam
Administration	Topical
Primary commercial risk	Generic substitution and antibiotic-stewardship restrictions
Key formulation variables	Solvent system, vehicle rheology, preservative system, packaging, drying time, skin irritation

Clindamycin phosphate is converted in the skin to active clindamycin. The phosphate group improves aqueous handling but does not eliminate formulation risks involving pH, microbial preservation, packaging, and skin tolerability.

What excipients are used in CLEOCIN T formulations?

The excipient profile varies by dosage form. The principal commercial formulation families use water, glycols, alcohols, surfactants, gelling agents, neutralizers, preservatives, and fatty alcohols.

CLEOCIN T solution

The solution presentation uses a relatively low-viscosity vehicle designed for rapid spreading and low residue. Labelled excipient systems have included propylene glycol, isostearyl alcohol, water, and methylparaben.[1]

The strategic advantages are simple manufacturing, fast application, and compatibility with acne-prone skin areas. The disadvantages are potential stinging, dryness, odor, and limited consumer acceptance for patients who prefer a cream or gel texture.

Propylene glycol can function as a solvent, humectant, and penetration-modifying excipient. It can also contribute to irritation or allergic contact dermatitis in susceptible patients. Isostearyl alcohol improves emolliency and feel but makes the product less aqueous and can complicate scale-up and packaging compatibility.

CLEOCIN T gel

The gel presentation generally relies on a carbomer-type polymer, water, propylene glycol, methylparaben, and a base such as sodium hydroxide for neutralization and viscosity development.[2]

The gel vehicle offers:

• Higher residence time than a solution
• Better dosing control
• Lower runoff
• Greater consumer familiarity in acne treatment
• A platform for alcohol-reduced or alcohol-free positioning

Carbomer concentration and neutralization determine viscosity, yield stress, spreadability, and the amount of product left on the skin. Excessive viscosity can reduce patient adherence by increasing tack or pilling. Insufficient viscosity can cause run-off and inconsistent dosing.

The gel is also more sensitive to manufacturing sequence. Polymer wetting, neutralization order, shear exposure, and air entrapment can materially affect the finished product.

CLEOCIN T lotion

The lotion format uses an emulsion-like system with water, fatty alcohols, surfactants, and solvent or humectant components. Cetostearyl alcohol, polysorbate-type surfactants, propylene glycol, and preservative systems are representative excipient categories associated with this presentation.[3]

The lotion has greater potential for cosmetic acceptability than a clear solution. It can reduce the perception of dryness and improve application over larger affected areas, including the trunk. The tradeoff is higher manufacturing complexity and greater sensitivity to emulsion stability, particle size, phase separation, and preservative distribution.

CLEOCIN T foam

Foam formulations require a specialized vehicle and package. The commercial value of foam is based on quick spreading, low residue, and ease of use over hair-bearing or extensive acne-affected areas. Foam products generally require a propellant or pressurized delivery system, surfactants, emollients, solvents, and a package capable of maintaining product performance throughout shelf life.

A foam is not simply a higher-value gel. It requires separate development work for:

• Foam density and collapse time
• Actuation force
• Canister and valve compatibility
• Propellant selection
• Temperature stability
• Dose uniformity
• Residual solvent and odor
• Transport and flammability controls

Which excipient attributes matter most for a CLEOCIN T generic?

The strongest generic strategy is unlikely to come from duplicating the active ingredient alone. The commercial product must match the reference product in performance while offering a meaningful improvement in usability or manufacturing economics.

Skin tolerability

Topical clindamycin products may cause dryness, burning, erythema, peeling, or irritation. The excipient system can intensify or reduce these effects.

Key optimization levers include:

Formulation lever	Commercial objective	Main risk
Reduce propylene glycol	Lower irritation potential	Solubility and preservation challenges
Reduce volatile alcohol	Less dryness and stinging	Slower drying and greater residue
Add humectant	Improve skin feel	Tackiness or microbial burden
Add emollient	Reduce roughness	Comedogenicity and phase instability
Use mild surfactant	Improve emulsion quality	Irritation or preservative interaction
Use alternative polymer	Improve spreadability	Regulatory comparability and scale-up risk
Use lower preservative load	Improve tolerability	Microbial failure
Use airless packaging	Reduce contamination exposure	Higher package cost

A formulation that reduces stinging without increasing greasiness could compete effectively in patients who discontinue topical antibiotics because of irritation.

Microbial preservation

Water-based topical products require a validated antimicrobial preservation strategy unless the package and formulation provide adequate protection through another mechanism.

Preservative selection must account for:

• Product pH
• Partitioning into oil or polymer phases
• Binding to packaging
• Compatibility with clindamycin phosphate
• Microbial challenge performance
• Skin sensitization potential
• Regional regulatory acceptance

Methylparaben appears in legacy CLEOCIN T formulation disclosures and labels. A modern product could evaluate alternative preservative systems, but any change requires preservative-effectiveness testing, stability data, and regulatory comparability work.[1-3]

pH and chemical stability

The product should maintain a pH range that supports clindamycin phosphate stability, preservative efficacy, skin tolerability, and vehicle performance. Carbomer gels are particularly dependent on neutralization conditions. Small pH changes can alter viscosity and preservative distribution.

A robust development program should monitor:

• Assay and related substances
• pH drift
• Viscosity
• Appearance and odor
• Preservative content
• Microbial limits
• Container closure interaction
• Delivered dose over shelf life

Sensory performance

For acne products, sensory attributes can materially affect adherence. Patients often prefer formulations that:

• Dry quickly
• Do not leave a visible film
• Do not pill under sunscreen or makeup
• Do not create excessive shine
• Have low odor
• Spread evenly with a small amount of product

This creates room for a "cosmetic elegance" strategy based on controlled rheology, low-residue emollients, and optimized evaporation rather than a new active ingredient.

What formulation patents could protect a CLEOCIN T competitor?

A competitor could seek patent protection for a specific composition, delivery system, manufacturing process, or use. The active ingredient itself is not the strongest area for new patent protection because clindamycin phosphate is an established active with extensive generic use.

Formulation patent opportunities

Potential claim areas include:

1. A clindamycin phosphate gel with a defined carbomer concentration and pH range.
2. A low-irritation solution with reduced glycol or alcohol content.
3. A preservative system that maintains antimicrobial effectiveness at a defined pH.
4. A foam with a specified propellant, solvent, and active concentration.
5. An emulsion with a defined droplet size and fatty-alcohol system.
6. An airless or metered package that limits contamination and improves dose uniformity.
7. A formulation with improved stability under accelerated temperature and humidity conditions.
8. A vehicle that reduces residue or improves compatibility with cosmetic products.
9. A combination product containing clindamycin and benzoyl peroxide.
10. A manufacturing process that improves polymer dispersion or reduces batch variability.

Patentability will depend on unexpected performance. A routine substitution of one solvent, polymer, or preservative for another may face obviousness challenges unless the applicant can show a measurable advantage, such as substantially lower irritation, improved stability, better delivery, or superior patient adherence.

Method-of-use patent opportunities

Potential method claims could target:

• Treatment of truncal acne
• Use in patients unable to tolerate a specific vehicle
• Reduced-frequency dosing
• Use with a defined benzoyl peroxide regimen
• Reduction of antibiotic resistance through combination therapy

Method-of-use protection is constrained by existing clinical practice and antibiotic-stewardship guidance. Claims requiring long-term topical antibiotic monotherapy would face commercial and regulatory limitations because acne guidelines generally favor combination treatment and limited antibiotic exposure.[4]

When does CLEOCIN T lose exclusivity?

CLEOCIN T has long passed the period of meaningful small-molecule regulatory exclusivity. The commercial market is therefore governed mainly by generic competition, formulation-specific approvals, manufacturing economics, and brand recognition.

Exclusivity category	CLEOCIN T position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current commercial relevance
Standard small-molecule patent barrier	No longer the primary barrier
Orange Book formulation protection	Must be assessed by dosage form and current listing
Generic competition	Established
Biosimilar exposure	Not applicable
Current commercial barrier	Formulation performance, supply, approval, and channel access

Topical products can retain commercial value after patent expiry because the reference product may have established prescribing habits, pharmacy recognition, and dosage-form differentiation. Those advantages are weaker when multiple approved generic presentations are available.

What is the Orange Book status of CLEOCIN T?

The Orange Book evaluates listed patents and regulatory exclusivity for approved drug products. For legacy topical clindamycin products, the practical issue is whether any unexpired patent remains listed against the relevant reference presentation and whether an ANDA applicant must address it through a Paragraph IV certification or another certification category.[5]

A product-specific assessment should distinguish among:

• Solution
• Gel
• Lotion
• Foam
• Clindamycin phosphate concentration
• Current reference-listed drug status
• Listed patents by NDA
• Approved generic presentation

Older CLEOCIN T patents are unlikely to block ordinary generic entry today. The more relevant barriers are formulation-specific patents filed by later applicants, device or package claims, and patents covering combination products rather than the legacy clindamycin product itself.

Which companies are challenging or competing with CLEOCIN T?

The competitive set includes generic manufacturers of clindamycin phosphate topical products and branded acne companies offering alternative antibiotics, retinoids, benzoyl peroxide products, and fixed-dose combinations.

Generic competition

Commercial competitors may include manufacturers with approved clindamycin phosphate solutions, gels, lotions, and foams. The competitive variables are:

• Wholesale acquisition price
• Pharmacy benefit coverage
• Dosage form availability
• Shortage history
• Contract manufacturing capacity
• Packaging format
• Retail substitution rates
• Product appearance and feel

A generic solution is easier to manufacture than a foam or stable emulsion. That can produce lower cost but also limits differentiation.

Branded alternatives

CLEOCIN T competes indirectly with:

• Clindamycin and benzoyl peroxide combinations
• Adapalene and benzoyl peroxide combinations
• Topical retinoids
• Azelaic acid products
• Topical minocycline
• Sarecycline and other oral antibiotics
• Over-the-counter benzoyl peroxide products

Combination products have a stronger commercial position when they address antibiotic resistance concerns and reduce the need for separate patient instructions. Their formulation and clinical development costs are higher.

What commercial opportunities exist for a CLEOCIN T excipient strategy?

1. Preservative-optimized generic

A product with a validated low-irritation preservative system could target patients who experience dryness or burning with legacy vehicles. The value proposition would depend on demonstrated tolerability and equivalent antimicrobial performance.

2. Alcohol-reduced gel

An alcohol-reduced gel could provide a more comfortable vehicle for facial acne. The main development issue is maintaining rapid drying without increasing tack, shine, or microbial risk.

3. Truncal-acne lotion or spray

Large-area acne treatment creates a delivery problem. A lotion, spray, or low-viscosity pump system could improve reach and coverage on the chest and back. Packaging ergonomics may be as important as the excipient system.

4. Cosmetic-compatible formulation

A fast-drying, low-pilling vehicle compatible with sunscreen and makeup could command a premium in cash-pay or dermatology channels. This strategy depends on sensory testing, not only standard pharmaceutical release tests.

5. Foam platform

Foam can offer differentiated handling and better coverage of hair-bearing skin. The opportunity is technically more demanding because the formulation and package are inseparable from the product.

6. Combination product

Clindamycin with benzoyl peroxide is commercially more defensible than clindamycin monotherapy. Benzoyl peroxide also addresses resistance-management concerns and is widely recognized in acne treatment.[4] The tradeoffs include oxidation, odor, discoloration, preservative interactions, and greater formulation complexity.

7. Private-label and teledermatology supply

A contract manufacturer could supply clindamycin phosphate topical products to teledermatology platforms, pharmacy brands, and dermatology distributors. The advantage is volume aggregation and channel-specific packaging. The limitation is high price pressure and dependence on reliable API and finished-product supply.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate for solution and gel products and higher for lotion and foam products.

Solution and gel

The principal risks are:

• Polymer dispersion
• Viscosity reproducibility
• Air entrapment
• pH control
• Preservative uniformity
• Filling accuracy
• Container compatibility

These products are accessible to experienced topical manufacturers. Their low technical barrier increases generic competition.

Lotion and emulsion

Emulsions require control of:

• Heating and cooling profiles
• Homogenization
• Droplet size
• Phase inversion
• Fatty-alcohol crystallization
• Preservative partitioning
• Freeze-thaw stability

A stable lotion can create a stronger commercial position because fewer manufacturers can consistently reproduce the reference product's sensory profile.

Foam

Foam has the highest barrier among the principal CLEOCIN T formats. The developer must control the drug product, valve, actuator, canister, propellant, and filling process as one system. Device changes can create regulatory and intellectual-property issues even when the active formulation is similar.

How strong is the CLEOCIN T patent estate?

The legacy CLEOCIN T estate is commercially weak relative to newer dermatology products because the active ingredient and core indication are mature. The strongest remaining protection opportunities are likely to arise from later-developed vehicles, packages, combination products, and manufacturing processes.

Estate component	Relative strength
Clindamycin phosphate composition	Low
Basic topical acne use	Low
Legacy solution vehicle	Low to moderate
Carbomer gel formulation	Low to moderate
Emulsion or lotion architecture	Moderate if narrowly defined
Foam delivery system	Moderate to strong if package-specific
Combination with benzoyl peroxide	Moderate, depending on claim scope
Low-irritation excipient system	Moderate if supported by unexpected data
Manufacturing process	Moderate if it produces measurable product advantages
Device or package claims	Moderate to strong for a differentiated delivery system

A new applicant should avoid relying on a single composition patent. A layered estate combining composition, use, process, package, and regulatory exclusivity is more resilient.

What generic launch scenarios exist for CLEOCIN T?

Low-cost standard generic

The fastest path is a conventional solution or gel closely matching the reference product. This approach minimizes development complexity but exposes the product to rapid price erosion.

Premium differentiated generic

A lower-irritation gel, cosmetic-compatible lotion, or improved pump presentation can support a higher price, although the product must obtain physician and payer acceptance.

Specialty foam launch

A foam can target dermatology practices and patients with truncal or hair-bearing acne. The product may achieve differentiation but requires greater capital, device expertise, and supply-chain control.

Combination launch

A clindamycin and benzoyl peroxide product has stronger clinical positioning but faces more demanding stability, packaging, and regulatory requirements. Benzoyl peroxide can oxidize or interact with excipients and packaging components, making development materially more complex.

Authorized-generic or licensed supply

An authorized generic arrangement can provide channel access and reduce branding costs. A license involving the reference sponsor or a major dermatology distributor could improve pharmacy acceptance, but the economic value depends on transfer pricing and market share.

What are the revenue and licensing opportunities?

CLEOCIN T itself is a mature product, so revenue exposure is more likely to arise from portfolio strategy than from recovery of legacy brand economics.

The most attractive opportunities are:

• A multi-product topical acne platform
• A private-label dermatology supply agreement
• A differentiated foam or pump product
• A clindamycin and benzoyl peroxide combination
• A contract manufacturing partnership
• Licensing of a vehicle, package, or preservative technology
• Expansion into truncal acne and large-area application

The best licensing asset would be a validated delivery technology that can support multiple topical actives. A platform that improves spreadability, reduces residue, or enables preservative reduction could be licensed beyond clindamycin to retinoids, azelaic acid, antifungals, and corticosteroids.

Key Takeaways

• CLEOCIN T is a mature clindamycin phosphate topical product with no meaningful new-chemical-entity exclusivity remaining.
• The main excipient opportunities are reduced irritation, improved cosmetic elegance, better large-area coverage, and more reliable preservation.
• Solution and gel products have lower manufacturing barriers and face intense generic competition.
• Lotion and foam products offer greater differentiation but require more complex process and package development.
• New patent value is more likely in formulation, delivery device, packaging, manufacturing, and combination-product claims than in clindamycin phosphate itself.
• Clindamycin and benzoyl peroxide combinations have stronger clinical positioning than clindamycin monotherapy but create substantial stability and packaging challenges.
• The most defensible commercial strategy is a differentiated topical platform rather than a single undifferentiated generic.

FAQs

Can propylene glycol be removed from a CLEOCIN T generic?

Yes, but removal may affect clindamycin phosphate solubility, skin delivery, viscosity, preservation, and sensory performance. A replacement solvent or humectant system would require comparative stability and performance development.

Is a preservative-free CLEOCIN T product commercially feasible?

It may be feasible with an appropriate package and microbial-control strategy, such as a validated unit-dose or contamination-limiting system. A multidose water-based product would face a higher microbial-risk burden.

Can a CLEOCIN T formulation be patented without changing clindamycin phosphate?

Yes. Protection may be available for a non-obvious excipient combination, pH range, delivery system, package, manufacturing process, or combination product supported by unexpected performance.

Is foam a better commercial dosage form than gel for topical clindamycin?

Foam offers stronger differentiation and may improve application over hair-bearing or extensive areas. Gel is generally simpler to manufacture and commercialize, making it more suitable for a price-driven generic strategy.

Does topical clindamycin have biosimilar risk?

No. Clindamycin phosphate is a small-molecule drug, so competition proceeds through generic drug pathways rather than the biosimilar pathway.

References

1. DailyMed. (n.d.). CLEOCIN T clindamycin phosphate topical solution prescribing information. U.S. National Library of Medicine.

2. DailyMed. (n.d.). CLEOCIN T clindamycin phosphate topical gel prescribing information. U.S. National Library of Medicine.

3. DailyMed. (n.d.). CLEOCIN T clindamycin phosphate topical lotion prescribing information. U.S. National Library of Medicine.

4. American Academy of Dermatology. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.